Realm Therapeutics - Realm Presents Data at ACAAI Scientific Meeting

October 30, 2017
RNS Number : 8994U
Realm Therapeutics PLC
30 October 2017



Realm Therapeutics plc

("Realm Therapeutics", "Realm" or the "Company")


Realm Therapeutics Presents Data Highlighting PR013's Efficacy Reducing Hyperemia and Pruritus Associated with Allergic Conjunctivitis at The American College of Allergy, Asthma, and Immunology (ACAAI) Scientific Meeting



30 October 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announced the Company presented data for PR013 at the American College of Allergy, Asthma, and Immunology (ACAAI) Scientific Meeting being held in Boston, Massachusetts. PR013 is a novel anti-inflammatory and immunomodulatory topical ocular solution in development for the treatment of Allergic Conjunctivitis (AC).


The poster presentation titled, "PR013 Reduces Hyperemia in Murine Models of Allergic Conjunctivitis and Both Histaminergic and Nonhistaminergic Itch in vitro" highlighted the significant efficacy of PR013 in reducing hyperemia (redness) and pruritus (itch). The poster is available on the Company's website,


"These results demonstrate the efficacy of PR013 in reducing both the redness associated with allergic conjunctivitis and in addressing multiple pathways of itch in vitro," commented Ethan Solomon, PhD, Director of Research and Development at Realm. "Treatment with PR013 following short ragweed allergen challenge resulted in a significant, dose dependent reduction in hyperemia. PR013 showed better control of hyperemia compared to the anti-histamine olopatadine (0.1%), and similar efficacy to high dose prednisolone (1%). In addition, treatment with PR013 resulted in a significant reduction in the response of dorsal root ganglia neurons to pruritogens known to stimulate both histamine-dependent and histamine-independent signalling pathways."


"By leveraging Realm's proprietary technology containing high concentrations of hypochlorous acid, PR013 has the potential to provide a novel therapeutic alternative to the current standard of care for AC, steroids and anti-histamines, which have drawbacks and deficiencies for patients," commented Alex Martin, Chief Executive Officer and Executive Director of Realm. "High dose steroids are associated with a potential risk of increased intra-ocular pressure, which can lead to glaucoma. Anti-histamines are only able to manage histamine-dependent itch pathways and fail to address histamine-independent itch. As itch is one of the most significant symptoms of AC, an effective therapeutic should treat both. PR013 has the potential to be a safe and effective alternative to current therapies, impacting itch from both of these pathways, and reducing the redness associated with AC. We look forward to advancing PR013 into Phase 2 studies by the end of 2017." 


AC affects up to 40% of the U.S. population and up to 20% of the population of Europe and Japan, including pediatrics. Realm recently submitted an IND and was allowed by the Food and Drug Administration to proceed into Phase 2 clinical studies of PR013 in AC and is on track to begin these studies by the end of the year.





Realm Therapeutics plc

+44 (0) 20 3727 1000

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

FTI Consulting

+44 (0) 20 3727 1000

Simon Conway / Mo Noonan

Argot Partners

+1 212 600 1902

Stephanie Marks


N+1 Singer (Nominated Adviser and Broker)


+44 (0) 20 7496 3000

Aubrey Powell / Lauren Kettle


About Realm Therapeutics


Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies to protect and improve the lives of adults and children.   The Company has initiated drug development programs, based on its proprietary hypochlorous acid technology at high concentrations.  The Company believes its formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas, including Dermatology and Ophthalmology.  



Forward Looking Statements


Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions.  Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.


This information is provided by RNS
The company news service from the London Stock Exchange

Search Investor Relations